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Abstract
Introduction: After a cholecystectomy, incidental gallbladder cancer (IGC) requires accurate imaging
studies to determine the actual extent of the disease to properly tailor subsequent treatment. The aim of
this study was to evaluate the utility of 18F-fluorodeoxyglucose positron emission tomography-computed
tomography (18FDG PET-CT) to provide optimal pre-treatment staging in patients with IGC.
Material and Methods: Between January 2006 and August 2008, all patients with IGC and at least
muscular layer invasion were studied with 18FDG PET-CT. The examination was considered positive when
the standardized uptake values (SUV) were 2.5. In all instances patients were offered to undergo
definitive exploration and possible radical resection.
Results: The series included 32 patients, 26 women and 6 men, with a median age of 57 years (range
30–81 years). The examination was performed at a median time of 6 weeks after cholecystectomy (range
2–52 weeks). 18FDG PET-CT was negative in 13 patients and positive in 19 patients: 9 with localized
potentially resectable disease (PRD) and in 10 with disseminated disease. Of the 13 patients with negative
PET-CT, 9 refused surgery and 4 underwent formal exploration: 3 patients were resected with no disease
identified in the final pathology report (FPR) and 1 was not resected as a result of peritoneal carcinoma-
tosis. Of the 9 with PRD, 4 patients refused reoperation and 5 underwent exploration: 3 were resected
with residual disease noted in the FPR and 2 did not undergo resection because of dissemination. Two
patients with disseminated disease were reoperated and in both instances disseminated disease was
confirmed. The median survival for the entire group was 20.3 months (range 1.6–32.9 months). The
median survival for those patients with negative PET-CT was 13.5 months (range 5.6–32.9 months), 6.2
months (range 1.6–18.7 months) for localized potentially resectable disease and 4.9 months (range 2–14.1
months) for disseminated disease (P < 0.003).
Conclusions: For patients presenting with stage T1b or greater IGC, the use of 18FDG PET-CT will help
reduce the number of patients undergoing non-therapeutic re-exploration and may help to determine the
likely prognosis. 18FDG PET-CT might be a useful tool for the selection of patients for potentially curative
treatment.
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Introduction
Gallbladder cancer (GC) is an aggressive and lethal malignancy.1
Most patients are diagnosed at an advanced stage, with clinically
evident disease and when curative surgical resection is not pos-
sible.2 In these patients, the only method of treatment is palliation
and the possibility of long-term survival is anecdotal.3
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Patients diagnosed with incidental gallbladder cancer (IGC)
(invasive carcinoma identified in the final pathology report) after
cholecystectomy for presumed benign disease, should have a
better prognosis4 than those with overt gallbladder malignancy.
Initial pathological study of the gallbladder would permit knowl-
edge of the extent of the disease in the gallbladder wall and permit
selection of patients for potentially curative resection. Previous
studies have showed that patients with pT1b or pT2 gallbladder
cancer may improve their chances of survival with radical
resection.5–7 However, in spite of the incidental diagnosis, many
patients will actually have non-localized disease for which radical
resection will have no impact on survival.4 For this reason, it is
appropriate to perform a pre-operative imaging study that might
help in the selection of patients for radical resection and likewise
avoid laparotomy in patients with disseminated disease.
Multiple studies have been used to evaluate the extent of the
disease with computed tomography (CT) and magnetic resonance
imaging (MRI) being the most frequently utilized.8 However, 18F-
fluorodeoxyglucose positron emission tomography (18FDG PET)
has been demonstrated to have value in properly staging select
tumors such as esophageal cancer, melanoma, colorectal cancer
and lymphoma.9 Recently, 18FDG PET plus CT has been reported
to improve the sensitivity to detect non-clinically evident meta-
static disease.10 As GC is a malignant tumour with a propensity to
early systemic spread, this imaging tool could prove to be useful in
identifying and selecting patients with disseminated disease not
amenable to curative resection.11,12
The aim of the present study was to evaluate the utility of 18FDG
PET-CT in providing optimal pre-treatment staging in patients
with incidental gallbladder cancer and to evaluate its role as a
prognostic tool.
Patients and methods
Patients
Between January 2006 and August 2008, a prospective study was
initiated in which all patients with IGC diagnosed after a laparo-
scopic or open cholecystectomy, and at least muscular layer inva-
sion, were re-staged with 18FDG PET-CT.
In all patients, a re-review of the pathological tissue of the
cholecystectomy specimen was performed to confirm the depth of
tumour invasion, the presence or absence of cystic lymph node
involvement and to precisely assess the surgical margin in both the
gallbladder bed and cystic duct. All patients were staged according
to the 2002 The American Joint Commission on Cancer tumour-
lymph node-metastasis (AJCC TNM) system.13
Definitions
Incidental gallbladder cancer
Cancer diagnosed during final pathologic review (FPR) after an
open or laparoscopic cholecystectomy for presumed benign
disease. The diagnosis of gallbladder cancer was not suspected at
the time of surgery.
Negative 18FDG PET-CT finding Examination without suspi-
cious lesions and normal 18FDG standardized uptake values
(SUV).
Positive 18FDG PET-CT finding Examination with suspicious
lesions and abnormal 18FDG uptake (SUV > 2.5). We categorized
FDG/PET findings as demonstrating a local, regional or systemic
pattern. Regional and systemic pattern are considered dissemi-
nated disease. Local disease confers lymph node compromise at
the hepatoduodenal ligament (pericoledochal), gallbladder liver
bed and/or cystic duct. Regional disease refers to suspicious lymph
nodes located at interaortocaval (IAO), hepatic artery or para
aortic bed. Systemic pattern includes the liver, peritoneal and extra
abdominal abnormal uptake.
18FDG PET-CT Technique Beginning the night before exami-
nation, patients were not allowed carbohydrates. On the day of the
examination, patients fasted for at least 6 h and drank at least 1
liter of water without sugar or saccharin. Diabetic patients had to
have a normal blood sugar level (<120 mg/dl).
All studies were performed in a PET-CT Siemens Biograph 6
(PET-CT HiRz, P3D; Siemens Medical System, Erlangen,
Germany) with 4-mm crystal detectors and multislice helical CT,
60 min after the intravenous (i.v.) administration of 370 MBq of
18FDG. All patients, unless there was a formal contraindication,
received i.v. iodinated contrast media immediately before the
acquisition of the CT portion of the study. Studies were consid-
ered positive when abnormal focal 18FDG uptake was seen in the
PET images, in the abscense of inflammatory changes on CT
(regardless of the SUV value). The examination was considered
positive when the SUV was  2.5.
Treatment In all instances of localized and potential resectable
disease, patients were offered definitive exploration and possible
radical re-resection. In patients with disseminated disease,
patients were offered a core biopsy to confirm metastatic disease.
All patients were followed until the end of the study or their death.
Surgical treatment In those patients with non-disseminated
disease at surgical exploration treatment included resection of
liver segments IVB and V, regional lymph node dissection (cystic,
pericoledochal, common hepatic artery and intercavoaortic (IAO)
lymph nodes) and common hepatic bile duct resection if there
was a positive cystic duct margin.
Statistical analysis The long-term survival was calculated using
the Kaplan–Meier method, log-rank and Cox’s test. A value of P <
0.05 was considered statistically significant. All living patients
were censored in the last follow up.
Results
During the study period, 53 patients with gallbladder cancer were
evaluated with 18FDG PET-CT. Thirty-two of these patients had
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IGC and compromise the study population reported in the
present study. The median age was 57 years (range 30–81 years),
with 26 women (80%) and 6 men (20%).
Pathological review of the cholecystectomy specimen revealed
31 adenocarcinomas and 1 squamous cell carcinoma. Four
patients had invasion of the muscular layer (T1b), 19 patients had
invasion of the perimuscular connective tissue (T2), 7 patients
had invasion of the serosal layer (T3) and 2 patients had com-
promise of gallbladder bed (T3). A cystic lymph node was iden-
tified in 18 patients (56.2%) and 10 patients were positive for
malignancy.
After the cholecystectomy, PET-CT was performed with a
median time of 6 weeks (range 2–52 weeks). In 13 patients, the
18FDG PET-CT finding was negative (Fig. 1) and in 19 patients it
was positive [localized and potentially resectable disease in 9
patients (Fig. 2) and disseminated disease in 10 patients (Fig. 3)].
The mean and the median SUV in those patients with positive
18FDG PET-CT findings were 7.45 and 7.1 (range 2.6–15.8). The
18FDG PET-CT was positive in the pericoledochal lymph nodes in
11 patients, gallbladder bed in 10 patients, liver (metastases) in 6
patients, IAO lymph nodes in 4 patients, peritoneum (carcinoma-
tosis) in 3 patients, lung (metastases) in 2 patients and the
common hepatic artery lymph nodes in 1 patient.
The 18FDG PET-CT findings changed the pre-test stage in 12
out of 32 patients (38%) (Table 1). In those patients with negative
FDG-PET-CT findings, nine refused surgery and four underwent
laparotomy with three patients resected for cure with no disease
identified at FPR and one was not resected because of peritoneal
carcinomatosis. This patient had a signet ring cell tumour and
localized small volume carcinomatosis.
In those nine patients with potentially resectable disease, four of
them refused reoperation and five underwent exploration (three
were resected with residual disease noted at the FPR and two did
not undergo resection because of carcinomatosis).
Two patients with disseminated disease were reoperated and in
both instances disseminated disease was confirmed.
Figure 1 An example of a 18F-fluorodeoxyglucose positron emission tomography-computed tomography (18FDG PET-CT) which showed no
evidence of residual disease (negative finding) in a patient whowas diagnosedwith an incidental gallbladder carcinoma after cholecystectomy
Figure 2 An example of a 18F-fluorodeoxyglucose positron emission tomography-computed tomography (18FDG PET-CT) which showed
evidence (positive finding) of localized disease (arrow) in a patient who was diagnosed with an incidental gallbladder carcinoma
aftercholecystectomy
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The median survival for the entire group was 20.3 months
(1.6–32.9 months). The median survival for those patients with
negative 18FDG PET-CT (n = 13) was 13.5 months (5.6–32.9
months) and 5.7 months (1.6–18.7 months) for those patients
with positive 18FDG PET-CT (n = 19) (P < 0.003) (Fig. 4).
The median survival for those patients with localized poten-
tially resectable disease (n = 9) was 6.2 months (1.6–18.7
months) and 4.9 months (2–14.1 months) for those with dis-
seminated disease (n = 10) identified by 18FDG PET-CT (P <
0.003) (Fig. 5).
Discussion
GC is the sixth most common gastrointestinal malignancy in the
United States and approximately 8500 new cases are diagnosed
annually.14 Patients with GC usually have advanced disease at the
time of diagnosis and only 15–47% are candidates for radical
resection.2 In our experience, 80% of the patients have metastatic
disease and only 20% have potentially resectable disease at time of
the diagnosis. Only half of the second group can be resected when
they undergo surgical exploration.
Patients with early gallbladder cancer are usually diag-
nosed incidentally upon pathological review of the elective
Table 1 Comparison and change in stage between pathological
stage before positron emission tomography-computed tomography
(PET CT) and PET-CT findings
Pre-test stage N° 18FDG
PET-CT findings
N°
T1b,2 or 3 + Nx 14
Negative 4
Localized 3
Disseminated* 7
IA or T1bN0M0 3
Negative 2
Localized* 1
IB or T2N0M0 5
Negative 4
Localized* 1
IIB or T1bN1M0 or
T2N1M0 or T3N1M0
10
Negative 3
Localized 4
Disseminated* 3
*change in stage: 12/32.
Figure 3 An example of a 18F-fluorodeoxyglucose positron emission tomography-computed tomography (18FDG PET-CT) which showed
evidence (positive finding) of disseminated disease (arrow) in a patient who was diagnosed with an incidental gallbladder carcinoma after
cholecystectomy
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cholecystectomy specimen and may have a better prognosis4 than
those patients who present with clinically apparent malignant
disease. In those patients with a T1b tumour (muscular layer
invasion), there is some controversy about the optimal treatment.
However, because this type of tumour is associated with lymph
node metastases in 15% of patients and some studies have shown
a recurrence rate of 30% with cholecystectomy alone compared
with 10% with extended resection, radical resection would appear
to be the treatment of choice.15 In those patients with T2 tumours
(perimuscular connective tissue layer invasion), one-third have
lymph node metastases and radical resection is considered appro-
priate in an attempt to optimize long-term survival.2 In those
patients with a T2 tumour and radical resection, Chijiiwa et al.16
showed a 5-year overall survival (OS) of 59% and 17% in those
without radical resection. In another study, in those patients with
radical resection, Fong et al.17 showed a 5-year OS of 61% and
19% in those with simple cholecystectomy. In those patients with
T3 or T4 tumours, long-term survival might be improved with
radical resection in very select cases, as shown by Behari et al.18 In
summary, patients with T1b, T2 and select T3 gallbladder cancer
could be suitable for re-exploration and eventual radical
resection.
In spite of radical surgical treatment, at least 15% of patients
with a T1b tumour, 40% of patients with a T2 tumour and 80%
with a T3 tumour will develop recurrent disease and will die in
follow-up. Jarnagin et al.19 showed in 54 patients with IGC, at a
median follow-up time of 24 months, a recurrence rate of 65%. In
81% of patients the recurrence was at a distant site. It is important
to note that the median time of disease recurrence was 11.5
months, 62% of patients within 12 months of surgery and 88% of
patients within 24 months. This relatively short time to recurrence
infers that disseminated disease was present at the time of chole-
cystectomy, becoming evident during the short-term follow-up in
the majority of patients. An accurate staging method in IGC is
critical to determine resectability, identify disseminated disease
and to avoid surgical exploration for those with unresectable
and/or disseminated disease.
Recently, CT and MRI have been the most common imaging
techniques to evaluate for local or distant extension of this disease
and for the relationship between localized tumour and either
nearby vascular structures or the biliary tree.8 However, both CT
and MRI have well-recognized limitations for the detection of
tumour recurrence or metastases, often related to tumour size, but
also including difficulty in differentiating residual/recurrent
tumour from surgically induced scarring or inflammatory
change.12 For these reasons, functional imaging with 18FDG
PET-CT prior to attempted curative intervention could improve
the pre-treatment selection of patients who might potentially
benefit from such interventions.
18FDG PET-CT has been useful as a staging tool in a variety of
malignancies such as esophageal, lymphoma, lung, breast, colorec-
tal, melanoma and head and neck cancer. The value of this test is
not only in providing information about the spread of the disease,
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Figure 4 Kaplan–Meier survival curves for patients with negative
[median (range) survival 13.5 (5.6–32.9) months] and positive
[median (range) survival 5.7 (1.6–18.7) months, P < 0.003] findings on
18F-fluorodeoxyglucose positron emission tomography-computed
tomography (18FDG-PET-CT) scans performed after the diagnosis of
incidental gallbladder cancer post cholecystectomy
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Figure 5 Kaplan–Meier survival curves for patients with no evidence
of residual disease [median (range) survival 13.5 (5.6–32.9) months],
localized potentially resectable disease [median (range) survival
6.2 (1.6–18.7) months] and disseminated disease [median (range)
survival 4.9 (2–14.1) months, P < 0.003] on 18F-fluorodeoxyglucose
positron emission tomography-computed tomography (18FDG-PET-
CT) scans performed after the diagnosis of incidental gallbladder
cancer post cholecystectomy
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but in the evaluation of treatment response and in the prediction
of long-term survival.20
There are a paucity of studies utilizing 18FDG PET and 18FDG
PET-CT in gallbladder cancer. Anderson et al.12 evaluated 14
patients with a diagnosis of gallbladder cancer with 18FDG PET. In
the evaluation of residual gallbladder carcinoma after cholecys-
tectomy, sensitivity and specificity were 78% and 80%, respec-
tively. There was one false-positive result in a patient who
underwent 18FDG PET within 1 month of cholecystectomy, and
two patients had false-negative findings. These patients had bulky
intra-abdominal metastasis and carcinomatosis. Sensitivity for
extra hepatic metastases was 56% and 18FDG PET detected carci-
nomatosis in only one out of six patients. As we demonstrated
in this study, one out of four reoperated patients with negative
18FDG PET-CT findings had carcinomatosis at the time of
re-exploration. 18FDG PET-CT would be not a good method for
identifying carcinomatosis, especially in those patients with small
volume carcinomatosis and signet ring cell tumours. In another
study, Corvera et al.,11 studied 31 patients with gallbladder cancer
diagnosed after cholecystectomy. In seven (23%) of these patients,
18FDG PET changed management by identifying metastatic
disease not seen in previous studies. However, in 12 of the other 24
operated patients, the disease could not be curatively resected
because of locally advanced or disseminated disease. More
recently, Shukla et al.21 studied 80 patients with IGC with 18FDG
PET-CT. Fifty-five (70%) of these patients had disseminated
disease and 24 (30%) patients had local and potentially resectable
disease. Twenty-one of these patients could be resected and in
seven (33%) of them, there was residual disease. The sensitivity
and positive predictive values of 18FDG PET-CT for residual
disease were 28.5% and 20%, respectively.
In this study, 18FDG PET-CT identified 10 (31.3%) patients
with disseminated disease and, as with the study of Corvera
et al.,11 changed surgical management in eight (25%) of them.
Also, after the review of the cholecystectomy FPR, 18FDG PET-CT
changed the pre-test stage of the disease in 37.5% patients to
identify localized or disseminated disease in those patients
without clinically evident disease.
This report is limited because only 9 out of 22 patients with
18FDG PET-CT findings of either no or localized disease under-
went surgical re-exploration. However, of these patients who were
re-explored, no residual disease was found in patients with a nega-
tive 18FDG PET-CT (except by one patient). Conversely, patients
with 18FDG PET-CT scans demonstrating either local or dissemi-
nated disease were found to have a residual tumour, although
sometimes patients with a localized tumor on 18FDG PET-CT
were found to have disseminated disease.
Importantly, 18FDG PET-CT accurately identified patients who
had a disseminated tumour pre-operatively, in this relatively small
study identifying patients who would not benefit from curative
attempts. These data suggest that patients with an apparently dis-
seminated tumour would benefit from limited means of verifica-
tion (e.g. needle biopsy, other imaging, etc.), thereby avoiding
futile aggressive attempts at a cure. However, the optimal staging
of IGC may be 18FDG PET-CT combined with laparoscopy
thus minimizing the risk of missing small volume peritoneal
disease.
In patients with a negative 18FDG PET-CT, attempts at surgery
with curative intent are warranted as our data demonstrate supe-
rior overall survival in this cohort. In patients with apparently
localized disease, re-exploration should be attempted, as these
patients have intermediate improvements in survival compared
with those with no evidence of disease and those with dissemi-
nated disease.
Finally, these results should be reproduced by others, particu-
larly in larger series, to confirm our findings. As a result of the
relatively low incidence of gallbladder carcinoma, this may require
a multi-institutional, prospective investigation.
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